Consun Pharmaceutical Group Limited (FRA:C1P)

Market Cap	1.09B
Revenue (ttm)	392.66M
Net Income (ttm)	120.48M
Shares Out	n/a
EPS (ttm)	0.14
PE Ratio	9.01
Forward PE	8.59
Dividend	0.11 (9.65%)
Ex-Dividend Date	Sep 5, 2024

Volume	707
Average Volume	514
Open	1.100
Previous Close	1.100
Day's Range	1.100 - 1.100
52-Week Range	0.071 - 1.330
Beta	n/a
RSI	52.15
Earnings Date	May 21, 2025

About FRA:C1P

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function ass...

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 3,164
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: C1P

Financial Performance

In 2024, FRA:C1P's revenue was 2.97 billion, an increase of 14.56% compared to the previous year's 2.59 billion. Earnings were 910.46 million, an increase of 16.05%.

Financial numbers in CNY